

Contact**T** +49 (0)89 747 266 0**F** +49 (0)89 776 424**E** Ehlich@maiwald.eu**Dr. Eva Ehlich****Partner****German Patent Attorney****European Patent Attorney****UPC Representative****Chemist**

Eva Ehlich represents European, US and Japanese companies in the chemical, biochemical and pharmaceutical sectors whom she advises and assists in drafting, prosecuting, defending, enforcing and challenging IP rights in Germany, Europe and worldwide. Along with preparing freedom-to-operate and validity analyses she has experience in patent litigation and strategic patent filing, SPCs, especially in the area of drug delivery, pharmaceuticals and medical uses (small molecules and biologics including vaccines) as well as in coordinating international patent portfolios and freedom-to-operate strategies. In this context she coordinates as hub-counsel team-lead large attorney teams including attorneys from Maiwald and international partner law firms. Eva Ehlich has received numerous recognitions for her professional activities as a patent attorney.

"Eva Ehlich is a brilliant, highly experienced and dedicated attorney combining an impressive degree of long-sightedness with exceptional attention to the countless details of a case. She gets great results and is also a nice person to work with."

- IAM Patent 1000, 2023

"An extremely safe pair of hands for complex IP issues and top-level portfolio strategy in the pharmaceutical and biotechnology space, Eva Ehlich is commercially and culturally astute and easily grapples with the complexities and politics of larger international projects."

- IAM 300, 2022

CAREER

since 2012	Partner, shareholder and managing director at Maiwald
since 2004	Patent attorney at Maiwald
2001 - 2004	Patent attorney trainee at Maiwald

EDUCATION

2023	Admitted to practice before the UPC
2006	Passed the US patent agent examination
2005	Admitted to practice as European patent attorney
2004	Admitted to practice as German patent attorney
2001 - 2004	Studied law for patent attorneys at University of Hagen
1998 - 2001	Doctoral degree in the field of chemistry from the Technical University of Munich
1992 - 1998	Studied chemistry at the Technical University of Munich

PRACTICE AREAS

- Pharma & Biotech
- Organic Chemistry & Polymers
- Inorganic & Construction Materials
- IP Consulting
- Patents & Utility Models

SERVICES

- Patent prosecution and portfolio management
- Filing strategies and drafting patent applications
- Freedom-to-operate and validity opinions
- Opposition and nullity proceedings
- Patent litigation

RECOGNITIONS

- Recommended in Legal 500 EMEA 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in Legal 500 Deutschland 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Listed in IAM Strategy 300 Global Leaders 2022, 2023, 2024
- Recommended by IAM Strategy 300 as the World's leading IP Strategist 2021, 2022, 2023
- Recommended in IAM Patent 1000 "World's Leading Patent Professionals" 2020, 2021, 2022, 2023
- Recommended in Handelsblatt | Best Lawyers "Germany's Best Lawyers" 2019, 2020, 2021, 2022, 2023
- Listed as "Excellent" in the Leaders League Rankings Germany 2022 in the categorie Patent Prosecution
- Recommended in MIP IP Stars 2017, 2018, 2019, 2020, 2021, 2022, 2023
- "Highly recommended attorney" in JUVE Patent Rankings Germany 2021, 2022, 2023
- Featured among Managing IP's Top 250 Women in IP 2022
- "Frequently recommended lawyer" in the JUVE Handbook of Commercial Law Firms 2017/ 2018, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022

PUBLICATIONS

- What is Horizon Europe about? (2021)
- R 0016/13 - A truly positive decision! (2015)
- Patente treiben Innovation und Fortschritt, 2021
- Germany: EBA Set to Hear Case on the Legality of the EPO's Video Proceedings, 2021
- JUVE Handbook 2021/2022: Co-publishing article on the topic of „Chancen und Stolpersteine bei Videoverhandlungen am EPA“

- Interview IAM Strategy 300 Global Leaders, 2023
- Maiwald makes the case for patent lawyers to learn something new: LiquidText, The Patent Lawyer (Annual 2024)
- T 0116/18 and a review after 10 months of G 2/21, Managing IP 2024
- Products eligible for the medical use format under the EPC: new insights, Managing IP 2024
- Reliance on a purported technical effect for inventive step – Quo vadis “plausibility” after G 2/21? epi Information, 1/2024

IMPORTANT CASES

- Opposition against EP 3 679 915 concerning a dengue vaccine (Opposition Division)
- Appeal T2303/19 concerning a vaccine composition (Board of Appeal)
- Appeal T1977/21 concerning attenuated viruses (Board of Appeal)
- Appeal T0489/20 concerning a transdermal system for treating pain (Board of Appeal)
- 2 BvR 561/18, 2 BvR 756/16, 2 BvR 786/15 regarding the independence of the Boards of Appeal (German Constitutional Court)
- R 02/15, R 05/15, R 08/13 regarding the independence of members of the Boards of Appeal and the right to be heard (Enlarged Board of Appeal)
- T1938/09 regarding a transdermal system for treating pain (Board of Appeal)
- 315 O 383/17 regarding a transdermal system for treating pain (District Court of Hamburg)
- 21 O 6972/16, 4c O 20/16 regarding a transdermal system for treating pain (district court of Munich)
- T0259/15 regarding a transdermal system for treating pain (Board of Appeal)
- T1676/08 regarding an oral controlled release pain medicament (Board of Appeal)

MEMBERSHIPS

- German Patent Attorney Association
- AIPPI
- epi
- FICPI
- GRUR

LANGUAGES

- German
- English